Search Results - "Bagul, Makarand"

Long‐term safety of perampanel and seizure outcomes in refractory partial‐onset seizures and secondarily generalized seizures: Results from phase III extension study 307 by Krauss, Gregory L., Perucca, Emilio, Ben‐Menachem, Elinor, Kwan, Patrick, Shih, Jerry J., Clément, Jean‐François, Wang, Xuefeng, Bagul, Makarand, Gee, Michelle, Zhu, Jin, Squillacote, David

“…Summary Objective To evaluate safety, tolerability, seizure frequency, and regional variations in treatment responses with the AMPA antagonist, perampanel, in…”
Get full text

A post hoc evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols by Chisari, Clara Grazia, Guadagno, Joe, Adjamian, Peyman, Vila Silvan, Carlos, Greco, Teresa, Bagul, Makarand, Patti, Francesco

“…Background: Over 80% of individuals with multiple sclerosis (MS) experience MS-associated spasticity (MSS). In many European countries, after failure of…”
Get full text

The attitudes, knowledge and confidence of healthcare professionals about cannabis-based products by Russo, Emilio, Agredano, Paula Martinez, Flachenecker, Peter, Lawthom, Charlotte, Munro, Duncan, Hindocha, Chandni, Bagul, Makarand, Trinka, Eugen

“…Use of cannabis-based products is becoming more frequent, and it is important that healthcare professionals are informed and confident about them when making…”
Get full text

Adjunctive perampanel in adolescents with inadequately controlled partial‐onset seizures: A randomized study evaluating behavior, efficacy, and safety by Lagae, Lieven, Villanueva, Vicente, Meador, Kimford J., Bagul, Makarand, Laurenza, Antonio, Kumar, Dinesh, Yang, Haichen

“…Summary Objective The noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptor antagonist perampanel was shown in phase III trials…”
Get full text

A evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols by Clara Grazia Chisari, Joe Guadagno, Peyman Adjamian, Carlos Vila Silvan, Teresa Greco, Makarand Bagul, Francesco Patti

“…Background: Over 80% of individuals with multiple sclerosis (MS) experience MS-associated spasticity (MSS). In many European countries, after failure of…”
Get full text

LONG-TERM SAFETY AND EFFICACY OF ZONISAMIDE VERSUS CARBAMAZEPINE MONOTHERAPY FOR TREATMENT OF PARTIAL SEIZURES IN ADULTS WITH NEWLY DIAGNOSED EPILEPSY: RESULTS OF A PHASE III, MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY by Baulac, Michel, Bagul, Makarand, Patten, Anna, Giorgi, Luigi

“…PurposeTo assess the long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for partial seizures in adults with newly diagnosed…”
Get full text

LONG-TERM SEIZURE OUTCOMES WITH PERAMPANEL IN REFRACTORY PARTIAL-ONSET SEIZURES AND SECONDARILY GENERALISED PARTIAL SEIZURES: 10 MONTHS ADDITIONAL DATA FROM EXTENSION STUDY 307 FOLLOWING THREE PHASE III CLINICAL TRIALS by Ben-Menachem, Elinor, Krauss, Gregory, Bagul, Makarand, Zhu, Jin, Gee, Michelle

“…PurposeExtending duration of analysis with up to two years perampanel exposure.MethodsWe report 7260 additional patient-months (cut-off Oct 2011) from…”
Get full text

LONG-TERM SAFETY OF PERAMPANEL: ADDITIONAL 10 MONTHS OF DATA FROM EXTENSION STUDY 307 IN PATIENTS WITH PARTIAL-ONSET SEIZURES AGED 12 AND ABOVE by Clément, Jean-François, Krauss, Gregory, Pillay, Neelan, McLachlan, Richard, Hwang, Paul, Bagul, Makarand, Zhu, Jin, Gee, Michelle

“…PurposeExtending perampanel long-term safety/tolerability data, with an additional 10 months (cut-off Oct 2011).MethodsParticipants in study 307 (NCT00735397)…”
Get full text